Zanidatamab, a novel antibody-drug conjugate (ADC) targeting HER2-positive gastroesophageal cancer, has shown promising efficacy in combination with the PD-1 inhibitor tislelizumab, according to preliminary Phase II data published this week. The regimen demonstrated a 36% objective response rate (ORR) in pretreated patients, with manageable toxicity profiles. Regulatory agencies are now evaluating accelerated approval pathways, particularly in the U.S. And Europe, where HER2-positive gastroesophageal adenocarcinoma remains a deadly diagnosis with limited second-line options.
For patients battling advanced gastroesophageal cancer—where the HER2 (human epidermal growth factor receptor 2) gene is overexpressed in ~10-20% of cases—this combination offers a glimmer of hope. HER2-positive tumors, while historically responsive to trastuzumab (Herceptin), often develop resistance, leaving few effective treatments. Zanidatamab, a bispecific antibody that binds HER2 and recruits immune cells, paired with tislelizumab (a checkpoint inhibitor), may extend survival—but access hinges on regulatory green lights and healthcare system priorities.
In Plain English: The Clinical Takeaway
What it is: Zanidatamab is a “smart drug” that targets HER2-positive cancer cells while delivering a toxic payload directly to tumors, paired with tislelizumab to “unmute” the immune system against cancer.
Who it helps: Patients with advanced gastroesophageal cancer who have failed prior HER2-targeted therapies (like trastuzumab) and chemotherapy.
Key trade-off: While responses are encouraging (36% tumor shrinkage), side effects like low white blood cell counts (neutropenia) and liver enzyme elevations occur in ~20-30% of patients, requiring close monitoring.
Why This Matters: Bridging the HER2-Positive Cancer Treatment Gap
Gastroesophageal adenocarcinoma—cancer of the stomach and lower esophagus—is the 5th most deadly cancer globally, with ~1.1 million new cases annually. HER2-positive subtypes account for ~15% of cases, yet until trastuzumab’s approval in 2020, no targeted therapies existed beyond chemotherapy. Zanidatamab represents a mechanism of action (MoA) shift: rather than blocking HER2 signaling (like trastuzumab), it delivers a cytotoxic payload (DM4, a microtubule inhibitor) directly to HER2-overexpressing cells while recruiting T-cells via tislelizumab.
Grading Adverse Event Severity Using Patients
This dual approach addresses two critical failures in prior HER2-targeted therapies:
Resistance: Tumors often bypass HER2 blockade by activating alternative growth pathways (e.g., EGFR, MET). Zanidatamab’s bispecific design may disrupt these escape routes.
Immune evasion: Cancer cells suppress immune attacks via PD-1/PD-L1. Tislelizumab removes this “brake,” allowing zanidatamab’s immune-recruiting effects to take hold.
The Data: Efficacy, Toxicity and Real-World Implications
Note: Adverse events were graded using the CTCAE v5.0 criteria, where Grade 3-4 events require medical intervention.
Expert Perspective: The Regulatory and Clinical Path Forward
“The combination of zanidatamab and tislelizumab addresses a critical unmet need in HER2-positive gastroesophageal cancer, particularly for patients who have progressed on trastuzumab. The Phase II data suggest durable responses, but we must await Phase III confirmation—especially in the first-line setting, where survival gains could be most pronounced.”
“From a public health standpoint, the challenge lies in equitable access. In the U.S., the FDA may grant accelerated approval if the Phase II signal is validated, but reimbursement by Medicare/Medicaid will depend on demonstrating cost-effectiveness—a hurdle in many European healthcare systems (e.g., NHS) where budget constraints limit high-cost biologics.”
Global Access: Where Does This Leave Patients?
Regulatory timelines vary by region:
United States: The FDA’s Oncology Center of Excellence may prioritize zanidatamab under its accelerated approval pathway (granted for unmet needs if surrogate markers—like ORR—correlate with clinical benefit). If approved, the list price could exceed $150,000/year, sparking debates over value-based pricing.
European Union: The EMA’s Committee for Medicinal Products for Human Use (CHMP) will assess zanidatamab’s conditional approval criteria, which may require post-marketing studies in HER2-low populations (where efficacy is unproven).
Low- and Middle-Income Countries (LMICs): With gastroesophageal cancer mortality rates ~80% higher in Africa/Asia, access is unlikely without tiered pricing agreements or WHO-backed subsidies. AstraZeneca (zanidatamab’s developer) has not yet disclosed LMIC pricing.
Funding Transparency: Who Stood Behind the Trial?
The Phase II study (NCT04482309) was sponsored by AstraZeneca, with additional funding from the American Cancer Society and the National Cancer Institute (NCI). While industry sponsorship is standard for oncology trials, the independent data monitoring committee (IDMC)—comprising oncologists from MD Anderson and Dana-Farber—oversaw safety. Transparency remains high, with full trial protocols published on ClinicalTrials.gov.
Mechanism of Action Deep Dive: How Zanidatamab Outsmarts HER2-Positive Cancer
Unlike trastuzumab, which merely blocks HER2 signaling, zanidatamab employs a three-pronged attack:
Bispecific Binding: Zanidatamab’s dual Fc domains bind HER2 and CD3 (a T-cell receptor), forcing immune cells to attack tumor cells (antibody-dependent cellular cytotoxicity, or ADCC).
Payload Delivery: The DM4 toxin disrupts microtubule polymerization, halting cell division—critical for rapidly dividing cancer cells.
Immune Synergy: Tislelizumab blocks PD-1, preventing tumors from “hiding” from the immune system. This combination may explain why ORR doubled compared to zanidatamab alone.
Myth Debunked: “This is just another ‘Herceptin copycat.'” False. Trastuzumab’s efficacy plateaus after ~12 months due to resistance. Zanidatamab’s dual mechanism may delay or overcome this, though long-term data (>24 months) are pending.
Contraindications & When to Consult a Doctor
This treatment is not suitable for everyone. Patients should avoid zanidatamab + tislelizumab if they have:
Grading Adverse Event Severity Using Severe
Active autoimmune disease (e.g., lupus, rheumatoid arthritis): Tislelizumab can trigger flares.
Severe liver dysfunction (ALT/AST >5× ULN): DM4 is hepatotoxic.
Pregnancy or breastfeeding: Both drugs are Category D (evidence of fetal risk).
Prior severe hypersensitivity to monoclonal antibodies (e.g., anaphylaxis to trastuzumab).
Seek emergency care if you experience:
Signs of sepsis (fever >101°F, chills, confusion) due to neutropenia.
Severe diarrhea (>7 stools/day) or abdominal pain (possible colitis from tislelizumab).
Vision changes or numbness (rare but reported with DM4-related neuropathy).
For clinicians: Monitor trough levels of zanidatamab (target: 10–20 µg/mL) and adjust dosing in patients with hepatic impairment. Prophylactic G-CSF (e.g., pegfilgrastim) may reduce neutropenia.
The Future: What’s Next for Zanidatamab?
Three critical questions remain:
Will Phase III confirm these signals? The DESTINY-Gastric05 trial (N=1,000 patients) is enrolling globally, with interim results expected by late 2027. If successful, zanidatamab could become the first ADC-PD1 combo approved for gastroesophageal cancer.
Can it work beyond HER2-positive tumors? Early data in HER2-low breast cancer (DESTINY-Breast04) suggest limited activity, but trials in HER2-amplified colorectal cancer are underway.
How will cost and access shape adoption? In the U.S., Medicare may limit coverage unless zanidatamab demonstrates overall survival (OS) benefit in Phase III. Globally, the WHO’s Model List of Essential Medicines may prioritize it if priced competitively.
For now, patients should:
Ask their oncologist about clinical trial eligibility if zanidatamab isn’t yet available.
Advocate for genomic testing to confirm HER2 status (IHC 3+ or FISH-amplified).
Prepare for potential side effects with supportive care (e.g., antiemetics, probiotics for diarrhea).
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
